Clinical trial readout dates for Dyne Therapeutics Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is July 2028.
| Phase 3 zeleciment basivarsen (DYNE-101) Myotonic Dystrophy Type 1 (DM1); DM1 · NCT07486934 | July 2028 Recruiting |
| Phase 1/2 DYNE-101 Myotonic Dystrophy Type 1 (DM1) · NCT05481879 | July 2029 Ongoing |
| Phase 3 Zeleciment Rostudirsen (DYNE-251) Duchenne Muscular Dystrophy (DMD); Muscular Dystrophy, Duchenne · NCT07608432 | December 2030 Recruiting |
| Phase 1/2 DYNE-251 Duchenne Muscular Dystrophy (DMD) · NCT05524883 | September 2031 Ongoing |
Dyne Therapeutics Inc. reported $1.13B in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-05). Its net loss for that quarter was $194M; at that rate the cash would last about 6 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.
| 8-K Results of Operations — earnings, may carry pipeline updates | 2026-11-05 |